Comparison of Microwave Ablation and Transarterial Chemoembolization for Single-Nodule Hepatocellular Carcinoma Smaller Than 5cm: A Propensity Score Matching Analysis

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–380. doi:10.1002/hep.2908628130846
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236. doi:10.1016/j.jhep.2018.03.01929628281
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. NCCN guidelines insights: hepatobiliary cancers, version 1. JNCCN. 2017;15:563–573.28476736
   PubMedGoogle Scholar
• Lucchina N, Tsetis D, Ierardi AM, et al. Current role of microwave ablation in the treatment of small hepatocellular carcinomas. Ann Gastroenterol. 2016;29:460–465.27708511
   PubMed Web of Science ®Google Scholar
• Violi NV, Duran R, Guiu B, et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomized controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2018;3:317–325. doi:10.1016/S2468-1253(18)30029-329503247
   PubMed Web of Science ®Google Scholar
• Donadon M, Solbiati L, Dawson L, et al. Hepatocellular carcinoma: the role of interventional oncology. Liver Cancer. 2016;6:34–43. doi:10.1159/00044934627995086
   PubMed Web of Science ®Google Scholar
• Alejandro F, María R, Jordi B. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314. doi:10.1016/S0140-6736(18)30010-229307467
   PubMed Web of Science ®Google Scholar
• Pomfret EA, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl. 2010;16:262–278. doi:10.1002/lt.v16:320209641
   PubMed Web of Science ®Google Scholar
• Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155–2166. doi:10.1111/liv.1281825752327
   PubMed Web of Science ®Google Scholar
• Brown KT, Do RK, Gonen M, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol. 2016;34:2046–2053. doi:10.1200/JCO.2015.64.082126834067
   PubMed Web of Science ®Google Scholar
• Terzi E, Golfieri R, Piscaglia F, et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J Hepatol. 2012;57:1258–1267. doi:10.1016/j.jhep.2012.07.02522871502
   PubMed Web of Science ®Google Scholar
• Yang HJ, Lee JH, Lee DH, et al. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. Radiology. 2014;271:909–918. doi:10.1148/radiol.1313176024520944
   PubMed Web of Science ®Google Scholar
• Lee SH, Jin YJ, Lee JW. Survival benefit of radiofrequency ablation for solitary (3–5cm) hepatocellular carcinoma. Medicine. 2017;96:44.
   Google Scholar
• Kim JW, Kim JH, Sung KB, et al. Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller. Am J Gastroenterol. 2014;109:1234–1240. doi:10.1038/ajg.2014.15224935276
   PubMed Web of Science ®Google Scholar
• Hsu CY, Huang YH, Chiou YY, et al. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Transpl. 2011;17:556–566. doi:10.1002/lt.2227321506244
   PubMed Web of Science ®Google Scholar
• Chen RX, Gan YH, Ge NL, et al. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching. J Gastroenterol Hepatol. 2016;31:442–449. doi:10.1111/jgh.1307726259976
   PubMed Web of Science ®Google Scholar
• Liu PH, Lee YH, Hsu CY, et al. Survival advantage of radiofrequency ablation over transarterial chemoembolization for patients with hepatocellular carcinoma and good performance status within the Milan criteria. Ann Surg Oncol. 2014;21:3835–3843. doi:10.1245/s10434-014-3831-224903236
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. doi:10.1055/s-0030-124713220175033
   PubMed Web of Science ®Google Scholar
• Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470. doi:10.1053/jhep.2001.2217211172350
   PubMed Web of Science ®Google Scholar
• Ahmed M, Solbiati L, Brace CL. Image-guided tumor ablation: standardization of terminology and reporting criteria – a 10-year update. Radiology. 2014;273:241–260. doi:10.1148/radiol.1413295824927329
   PubMed Web of Science ®Google Scholar
• Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol. 2003;14:S199–S202. doi:10.1097/01.RVI.0000094584.83406.3e14514818
   PubMed Web of Science ®Google Scholar
• Zhang MK, Ma HM, Zhang J, et al. Comparison of microwave ablation and hepatic resection for hepatocellular carcinoma: a meta-analysis. Onco Targets Ther. 2017;10:4829–4839. doi:10.2147/OTT29042794
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Di Maso M, Muscatiello N. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia. 2016;32:339–344. doi:10.3109/02656736.2015.112743426794414
   PubMed Web of Science ®Google Scholar
• Chen QF, Jia ZY, Yang ZQ, Fan WL, Shi HB. Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-microwave ablation therapy for hepatocellular carcinoma tumors ≤5 cm: a propensity analysis at a single center. Cardiovasc Intervent Radiol. 2017;40:1748–1755. doi:10.1007/s00270-017-1736-828681222
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943. doi:10.1016/j.jhep.2011.12.00122424438
   PubMed Web of Science ®Google Scholar
• Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32:348–359.23397536
   PubMed Web of Science ®Google Scholar
• Terzi E, Piscaglia F, Forlani L, et al. TACE performed in patients with a single nodule of hepatocellular carcinoma. BMC Cancer. 2014;14:601. doi:10.1186/1471-2407-14-60125139639
   PubMed Web of Science ®Google Scholar
• Wright AS, Lee FT, Mahvi DM. Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis. Ann Surg Oncol. 2003;10:275–283. doi:10.1245/ASO.2003.03.04512679313
   PubMed Web of Science ®Google Scholar
• Chu KF, Dupuy DE. Thermal ablation of tumors: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14:199–208. doi:10.1038/nrc367224561446
   PubMed Web of Science ®Google Scholar
• Sato M, Tateishi R, Yasunaga H, et al. Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patients. J Gastroenterol. 2012;47:1125–1133. doi:10.1007/s00535-012-0569-022426637
   PubMed Web of Science ®Google Scholar